人福医药：甲泼尼龙片获批

Core Viewpoint - The approval of Methylprednisolone tablets by the National Medical Products Administration marks a significant milestone for the company, allowing it to sell the product in the Chinese market and enhancing its product portfolio [1] Group 1: Product Approval - The company's subsidiary, Jiulong Renfu, has received the drug registration certificate for Methylprednisolone tablets [1] - The product is indicated for the treatment of various diseases, including rheumatic diseases, collagen diseases, and skin diseases [1] Group 2: Financial and Market Impact - The company submitted the marketing authorization application in July 2024, which has been accepted [1] - Cumulative R&D investment for this project has reached approximately 12 million yuan [1] - According to data from Minet, the estimated national sales for Methylprednisolone tablets in 2024 is around 200 million yuan [1] Group 3: Strategic Implications - The approval signifies the company's capability to market the drug in China, thereby enriching its product line [1]